Epidemiology and pathophysiology of mitral valve prolapse: New insights into disease progression, genetics, and molecular basis

Circulation

Volumn 129, Issue 21, 2014, Pages 2158-2170

  Delling, Francesca N ^a,b   Vasan, Ramachandran S ^a,c  

^a FRAMINGHAM HEART STUDY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mitral valve; Mitral valve insufficiency; Mitral valve prolapse

Indexed keywords

CLINICAL CLASSIFICATION; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MITRAL VALVE PROLAPSE; MOLECULAR BIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; MITRAL VALVE PROLAPSE;

ANIMALS; DISEASE PROGRESSION; HUMANS; MITRAL VALVE PROLAPSE;

EID: 84901435325     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.006702     Document Type: Review

References (107)

1. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999; 341 1-7.
2. Devereux RB, Jones EC, Roman MJ, Howard BV, Fabsitz RR, Liu JE, Palmieri V, Welty TK, Lee ET. Prevalence and correlates of mitral valve prolapse in a population-based sample of American Indians the Strong Heart Study. Am J Med. 2001; 111 679-685.
3. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001; 104 2525-2532.
4. Tamura K, Fukuda Y, Ishizaki M, Masuda Y, Yamanaka N, Ferrans VJ. Abnormalities in elastic fibers and other connective-tissue components of floppy mitral valve. Am Heart J. 1995; 129 1149-1158.
5. Devereux RB, Kramer-Fox R, Shear MK, Kligfield P, Pini R, Savage DD. Diagnosis and classification of severity of mitral valve prolapse methodologic, biologic, and prognostic considerations. Am Heart J. 1987; 113 1265-1280.
6. Zuppiroli A, Rinaldi M, Kramer-Fox R, Favilli S, Roman MJ, Devereux RB. Natural history of mitral valve prolapse. Am J Cardiol. 1995; 75 1028-1032.
7. Avierinos JF, Detaint D, Messika-Zeitoun D, Mohty D, Enriquez-Sarano M. Risk, determinants, and outcome implications of progression of mitral regurgitation after diagnosis of mitral valve prolapse in a single community. Am J Cardiol. 2008; 101 662-667.
8. Grau JB, Pirelli L, Yu PJ, Galloway AC, Ostrer H. The genetics of mitral valve prolapse. Clin Genet. 2007; 72 288-295.
9. Barlow JB, Pocock WA. The significance of late systolic murmurs and mid-late systolic clicks. Md State Med J. 1963; 12 76-77.
10. Criley JM, Lewis KB, Humphries JO, Ross RS. Prolapse of the mitral valve clinical and cine-angiocardiographic findings. Br Heart J. 1966; 28 488-496.
11. Waller BF, Morrow AG, Maron BJ, Del Negro AA, Kent KM, McGrath FJ, Wallace RB, McIntosh CL, Roberts WC. Etiology of clinically isolated, severe, chronic, pure mitral regurgitation analysis of 97 patients over 30 years of age having mitral valve replacement. Am Heart J. 1982; 104(pt 1) 276-288.
12. Devereux RB, Brown WT, Kramer-Fox R, Sachs I. Inheritance of mitral valve prolapse effect of age and sex on gene expression. Ann Intern Med. 1982; 97 826-832.
13. Strahan NV, Murphy EA, Fortuin NJ, Come PC, Humphries JO. Inheritance of the mitral valve prolapse syndrome discussion of a threedimensional penetrance model. Am J Med. 1983; 74 967-972.
14. Kyndt F, Gueffet JP, Probst V, Jaafar P, Legendre A, Le Bouffant F, Toquet C, Roy E, McGregor L, Lynch SA, Newbury-Ecob R, Tran V, Young I, Trochu JN, Le Marec H, Schott JJ. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation. 2007; 115 40-49.
15. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008; 118 e523-e661.
16. Bonow RO, Carabello BA, Kanu C, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006; 114 e84-e231.
17. Devereux RB, Kramer-Fox R, Brown WT, Shear MK, Hartman N, Kligfield P, Lutas EM, Spitzer MC, Litwin SD. Relation between clinical features of the mitral prolapse syndrome and echocardiographically documented mitral valve prolapse. J Am Coll Cardiol. 1986; 8 763-772.
18. Boudoulas H. Mitral valve prolapse etiology, clinical presentation and neuroendocrine function. J Heart Valve Dis. 1992; 1 175-188.
19. Chesler E, King RA, Edwards JE. The myxomatous mitral valve and sudden death. Circulation. 1983; 67 632-639.
20. Lichodziejewska B, K?o? J, Rezler J, Grudzka K, D?uzniewska M, Budaj A, Ceremuzy?ski L. Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation. Am J Cardiol. 1997; 79 768-772.
21. Zdrojewski TR, Wyrzykowski B, Krupa-Wojciechowska B. Reninaldosterone regulation during upright posture in young men with mitral valve prolapse syndrome. J Heart Valve Dis. 1995; 4 236-241.
22. Weis AJ, Salcedo EE, Stewart WJ, Lever HM, Klein AL, Thomas JD. Anatomic explanation of mobile systolic clicks implications for the clinical and echocardiographic diagnosis of mitral valve prolapse. Am Heart J. 1995; 129 314-320.
23. Savage DD, Garrison RJ, Devereux RB, Castelli WP, Anderson SJ, Levy D, McNamara PM, Stokes J 3rd, Kannel WB, Feinleib M. Mitral valve prolapse in the general population, 1 epidemiologic features the Framingham Study. Am Heart J. 1983; 106 571-576.
24. Savage DD, Devereux RB, Garrison RJ, Castelli WP, Anderson SJ, Levy D, Thomas HE, Kannel WB, Feinleib M. Mitral valve prolapse in the general population, 2 clinical features the Framingham Study. Am Heart J. 1983; 106 577-581.
25. Warth DC, King ME, Cohen JM, Tesoriero VL, Marcus E, Weyman AE. Prevalence of mitral valve prolapse in normal children. J Am Coll Cardiol. 1985; 5 1173-1177.
26. Levine RA, Stathogiannis E, Newell JB, Harrigan P, Weyman AE. Reconsideration of echocardiographic standards for mitral valve prolapse lack of association between leaflet displacement isolated to the apical four chamber view and independent echocardiographic evidence of abnormality. J Am Coll Cardiol. 1988; 11 1010-1019.
27. Carpentier A. Cardiac valve surgery the "French correction". J Thorac Cardiovasc Surg. 1983; 86 323-337.
28. Foster GP, Isselbacher EM, Rose GA, Torchiana DF, Akins CW, Picard MH. Accurate localization of mitral regurgitant defects using multiplane transesophageal echocardiography. Ann Thorac Surg. 1998; 65 1025-1031.
29. Kumar N, Kumar M, Duran CM. A revised terminology for recording surgical findings of the mitral valve. J Heart Valve Dis. 1995; 4 70-75.
30. Shah PM. Current concepts in mitral valve prolapse-diagnosis and management. J Cardiol. 2010; 56 125-133.
31. Biaggi P, Jedrzkiewicz S, Gruner C, Meineri M, Karski J, Vegas A, Tanner FC, Rakowski H, Ivanov J, David TE, Woo A. Quantification of mitral valve anatomy by three-dimensional transesophageal echocardiography in mitral valve prolapse predicts surgical anatomy and the complexity of mitral valve repair. J Am Soc Echocardiogr. 2012; 25 758-765.
32. Han Y, Peters DC, Salton CJ, Bzymek D, Nezafat R, Goddu B, Kissinger KV, Zimetbaum PJ, Manning WJ, Yeon SB. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc Imaging. 2008; 1 294-303.
33. Gelfand EV, Hughes S, Hauser TH, Yeon SB, Goepfert L, Kissinger KV, Rofsky NM, Manning WJ. Severity of mitral and aortic regurgitation as assessed by cardiovascular magnetic resonance optimizing correlation with Doppler echocardiography. J Cardiovasc Magn Reson. 2006; 8 503-507.
34. Delling FN, Kang LL, Yeon SB, Kissinger KV, Goddu B, Manning WJ, Han Y. CMR predictors of mitral regurgitation in mitral valve prolapse. JACC Cardiovasc Imaging. 2010; 3 1037-1045.
35. Sanfilippo AJ, Harrigan P, Popovic AD, Weyman AE, Levine RA. Papillary muscle traction in mitral valve prolapse quantitation by two-dimensional echocardiography. J Am Coll Cardiol. 1992; 19 564-571.
36. Gornick CC, Tobler HG, Pritzker MC, Tuna IC, Almquist A, Benditt DG. Electrophysiologic effects of papillary muscle traction in the intact heart. Circulation. 1986; 73 1013-1021.
37. Dolan AL, Mishra MB, Chambers JB, Grahame R. Clinical and echocardiographic survey of the Ehlers-Danlos syndrome. Br J Rheumatol. 1997; 36 459-462.
38. Hortop J, Tsipouras P, Hanley JA, Maron BJ, Shapiro JR. Cardiovascular involvement in osteogenesis imperfecta. Circulation. 1986; 73 54-61.
39. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, De Backer JF, Oswald GL, Symoens S, Manouvrier S, Roberts AE, Faravelli F, Greco MA, Pyeritz RE, Milewicz DM, Coucke PJ, Cameron DE, Braverman AC, Byers PH, De Paepe AM, Dietz HC. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006; 355 788-798.
40. Roman MJ, Devereux RB, Kramer-Fox R, Spitzer MC. Comparison of cardiovascular and skeletal features of primary mitral valve prolapse and Marfan syndrome. Am J Cardiol. 1989; 63 317-321.
41. Rubegni P, Mondillo S, De Aloe G, Agricola E, Bardelli AM, Fimiani M. Mitral valve prolapse in healthy relatives of patients with familial pseudoxanthoma elasticum. Am J Cardiol. 2000; 85 1268-1271.
42. van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, Hoedemaekers YM, Willemsen R, Severijnen LA, Venselaar H, Vriend G, Pattynama PM, Collee M, Majoor-Krakauer D, Poldermans D, Frohn-Mulder IM, Micha D, Timmermans J, Hilhorst-Hofstee Y, Bierma-Zeinstra SM, Willems PJ, Kros JM, Oei EH, Oostra BA, Wessels MW, Bertoli-Avella AM. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011; 43 121-126.
43. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy recent observations regarding the specificity of three hallmarks of the disease asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet. Am J Cardiol. 1980; 45 141-154.
44. Nascimento R, Freitas A, Teixeira F, Pereira D, Cardoso A, Dinis M, Mendonça I. Is mitral valve prolapse a congenital or acquired disease? Am J Cardiol. 1997; 79 226-227.
45. Hickey AJ, Wilcken DE. Age and the clinical profile of idiopathic mitral valve prolapse. Br Heart J. 1986; 55 582-586.
46. Flack JM, Kvasnicka JH, Gardin JM, Gidding SS, Manolio TA, Jacobs DR Jr. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults the CARDIA study. Am Heart J. 1999; 138(pt 1) 486-492.
47. Theal M, Sleik K, Anand S, Yi Q, Yusuf S, Lonn E. Prevalence of mitral valve prolapse in ethnic groups. Can J Cardiol. 2004; 20 511-515.
48. Zua MS, Dziegielewski SF. Epidemiology of symptomatic mitral valve prolapse in black patients. J Natl Med Assoc. 1995; 87 273-275.
49. Ogawa S, Hayashi J, Sasaki H, Tani M, Akaishi M, Mitamura H, Sano M, Hoshino T, Handa S, Nakamura Y. Evaluation of combined valvular prolapse syndrome by two-dimensional echocardiography. Circulation. 1982; 65 174-180.
50. Taub CC, Stoler JM, Perez-Sanz T, Chu J, Isselbacher EM, Picard MH, Weyman AE. Mitral valve prolapse in Marfan syndrome an old topic revisited. Echocardiography. 2009; 26 357-364.
51. Attias D, Stheneur C, Roy C, Collod-Béroud G, Detaint D, Faivre L, Delrue MA, Cohen L, Francannet C, Béroud C, Claustres M, Iserin F, Khau Van Kien P, Lacombe D, Le Merrer M, Lyonnet S, Odent S, Plauchu H, Rio M, Rossi A, Sidi D, Steg PG, Ravaud P, Boileau C, Jondeau G. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation. 2009; 120 2541-2549.
52. Lebwohl MG, Distefano D, Prioleau PG, Uram M, Yannuzzi LA, Fleischmajer R. Pseudoxanthoma elasticum and mitral-valve prolapse. N Engl J Med. 1982; 307 228-231.
53. Petrone RK, Klues HG, Panza JA, Peterson EE, Maron BJ. Coexistence of mitral valve prolapse in a consecutive group of 528 patients with hypertrophic cardiomyopathy assessed with echocardiography. J Am Coll Cardiol. 1992; 20 55-61.
54. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992; 85 1651-1660.
55. Hagège AA, Bruneval P, Levine RA, Desnos M, Neamatalla H, Judge DP. The mitral valve in hypertrophic cardiomyopathy old versus new concepts. J Cardiovasc Transl Res. 2011; 4 757-766.
56. Avierinos JF, Gersh BJ, Melton LJ 3rd, Bailey KR, Shub C, Nishimura RA, Tajik AJ, Enriquez-Sarano M. Natural history of asymptomatic mitral valve prolapse in the community. Circulation. 2002; 106 1355-1361.
57. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006; 113 2238-2244.
58. Ling LH, Enriquez-Sarano M, Seward JB, Orszulak TA, Schaff HV, Bailey KR, Tajik AJ, Frye RL. Early surgery in patients with mitral regurgitation due to flail leaflets a long-term outcome study. Circulation. 1997; 96 1819-1825.
59. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005; 352 875-883.
60. Enriquez-Sarano M, Basmadjian AJ, Rossi A, Bailey KR, Seward JB, Tajik AJ. Progression of mitral regurgitation a prospective Doppler echocardiographic study. J Am Coll Cardiol. 1999; 34 1137-1144.
61. Grigioni F, Tribouilloy C, Avierinos JF, Barbieri A, Ferlito M, Trojette F, Tafanelli L, Branzi A, Szymanski C, Habib G, Modena MG, Enriquez-Sarano M; MIDA Investigators. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. JACC Cardiovasc Imaging. 2008; 1 133-141.
62. Ling LH, Enriquez-Sarano M, Seward JB, Tajik AJ, Schaff HV, Bailey KR, Frye RL. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med. 1996; 335 1417-1423.
63. Avierinos JF, Inamo J, Grigioni F, Gersh B, Shub C, Enriquez-Sarano M. Sex differences in morphology and outcomes of mitral valve prolapse. Ann Intern Med. 2008; 149 787-795.
64. Schoen FJ. Evolving concepts of cardiac valve dynamics the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation. 2008; 118 1864-1880.
65. Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol. 2007; 171 1407-1418.
66. Bischoff J, Aikawa E. Progenitor cells confer plasticity to cardiac valve endothelium. J Cardiovasc Transl Res. 2011; 4 710-719.
67. Salhiyyah K, Yacoub MH, Chester AH. Cellular mechanisms in mitral valve disease. J Cardiovasc Transl Res. 2011; 4 702-709.
68. Grande-Allen KJ, Griffin BP, Calabro A, Ratliff NB, Cosgrove DM 3rd, Vesely I. Myxomatous mitral valve chordae, II selective elevation of glycosaminoglycan content. J Heart Valve Dis. 2001; 10 325-332.
69. Barber JE, Ratliff NB, Cosgrove DM 3rd, Griffin BP, Vesely I. Myxomatous mitral valve chordae, I mechanical properties. J Heart Valve Dis. 2001; 10 320-324.
70. Fornes P, Heudes D, Fuzellier JF, Tixier D, Bruneval P, Carpentier A. Correlation between clinical and histologic patterns of degenerative mitral valve insufficiency a histomorphometric study of 130 excised segments. Cardiovasc Pathol. 1999; 8 81-92.
71. Brown CB, Boyer AS, Runyan RB, Barnett JV. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science. 1999; 283 2080-2082.
72. Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, Epstein JA, de Crombrugghe B. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A. 2004; 101 6502-6507.
73. de la Pompa JL, Timmerman LA, Takimoto H, Yoshida H, Elia AJ, Samper E, Potter J, Wakeham A, Marengere L, Langille BL, Crabtree GR, Mak TW. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature. 1998; 392 182-186.
74. Hurlstone AF, Haramis AP, Wienholds E, Begthel H, Korving J, Van Eeden F, Cuppen E, Zivkovic D, Plasterk RH, Clevers H. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature. 2003; 425 633-637.
75. Schilham MW, Oosterwegel MA, Moerer P, Ya J, de Boer PA, van de Wetering M, Verbeek S, Lamers WH, Kruisbeek AM, Cumano A, Clevers H. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature. 1996; 380 711-714.
76. Disatian S, Ehrhart EJ 3rd, Zimmerman S, Orton EC. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation. J Heart Valve Dis. 2008; 17 402-411.
77. Geirsson A, Singh M, Ali R, Abbas H, Li W, Sanchez JA, Hashim S, Tellides G. Modulation of transforming growth factor-beta signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. Circulation. 2012; 126 S189-S197.
78. Hulin A, Deroanne CF, Lambert CA, Dumont B, Castronovo V, Defraigne JO, Nusgens BV, Radermecker MA, Colige AC. Metallothioneindependent up-regulation of TGF-?2 participates in the remodelling of the myxomatous mitral valve. Cardiovasc Res. 2012; 93 480-489.
79. Sainger R, Grau JB, Branchetti E, Poggio P, Seefried WF, Field BC, Acker MA, Gorman RC, Gorman JH 3rd, Hargrove CW 3rd, Bavaria JE, Ferrari G. Human myxomatous mitral valve prolapse role of bone morphogenetic protein 4 in valvular interstitial cell activation. J Cell Physiol. 2012; 227 2595-2604.
80. Millington-Sanders C, Meir A, Lawrence L, Stolinski C. Structure of chordae tendineae in the left ventricle of the human heart. J Anat. 1998; 192(pt 4) 573-581.
81. Kimura N, Shukunami C, Hakuno D, Yoshioka M, Miura S, Docheva D, Kimura T, Okada Y, Matsumura G, Shin'oka T, Yozu R, Kobayashi J, Ishibashi-Ueda H, Hiraki Y, Fukuda K. Local tenomodulin absence, angiogenesis, and matrix metalloproteinase activation are associated with the rupture of the chordae tendineae cordis. Circulation. 2008; 118 1737-1747.
82. Bowers D. Pathogenesis of primary abnormalities of the mitral valve in Marfan's syndrome. Br Heart J. 1969; 31 679-683.
83. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, Stetten G, Meyers DA, Francomano CA. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991; 352 337-339.
84. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, Allard D, Varret M, Claustres M, Morisaki H, Ihara M, Kinoshita A, Yoshiura K, Junien C, Kajii T, Jondeau G, Ohta T, Kishino T, Furukawa Y, Nakamura Y, Niikawa N, Boileau C, Matsumoto N. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004; 36 855-860.
85. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC. TGFbeta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004; 114 1586-1592.
86. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312 117-121.
87. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ. Losartan reduces aortic dilatation rate in adults with Marfan syndrome a randomized controlled trial. Eur Heart J. 2013; 34 3491-3500.
88. Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L; Pediatric Heart Network Investigators. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007; 154 624-631.
89. Lacro RV, Guey LT, Dietz HC, Pearson GD, Yetman AT, Gelb BD, Loeys BL, Benson DW, Bradley TJ, De Backer J, Forbus GA, Klein GL, Lai WW, Levine JC, Lewin MB, Markham LW, Paridon SM, Pierpont ME, Radojewski E, Selamet Tierney ES, Sharkey AM, Wechsler SB, Mahony L; Pediatric Heart Network Investigators. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J. 2013; 165 828-835. e3.
90. Rajan S, Williams SS, Jagatheesan G, Ahmed RP, Fuller-Bicer G, Schwartz A, Aronow BJ, Wieczorek DF. Microarray analysis of gene expression during early stages of mild and severe cardiac hypertrophy. Physiol Genomics. 2006; 27 309-317.
91. Norris RA, Borg TK, Butcher JT, Baudino TA, Banerjee I, Markwald RR. Neonatal and adult cardiovascular pathophysiological remodeling and repair developmental role of periostin. Ann N Y Acad Sci. 2008; 1123 30-40.
92. Zuppiroli A, Roman MJ, O'Grady M, Devereux RB. A family study of anterior mitral leaflet thickness and mitral valve prolapse. Am J Cardiol. 1998; 82 823-826, A10.
93. Henney AM, Tsipouras P, Schwartz RC, Child AH, Devereux RB, Leech GJ. Genetic evidence that mutations in the COL1A1, COL1A2, COL3A1, or COL5A2 collagen genes are not responsible for mitral valve prolapse. Br Heart J. 1989; 61 292-299.
94. Wordsworth P, Ogilvie D, Akhras F, Jackson G, Sykes B. Genetic segregation analysis of familial mitral valve prolapse shows no linkage to fibrillar collagen genes. Br Heart J. 1989; 61 300-306.
95. Disse S, Abergel E, Berrebi A, Houot AM, Le Heuzey JY, Diebold B, Guize L, Carpentier A, Corvol P, Jeunemaitre X. Mapping of a first locus for autosomal dominant myxomatous mitral-valve prolapse to chromosome 16p11. 2-p12. 1. Am J Hum Genet. 1999; 65 1242-1251.
96. Freed LA, Acierno JS Jr, Dai D, Leyne M, Marshall JE, Nesta F, Levine RA, Slaugenhaupt SA. A locus for autosomal dominant mitral valve prolapse on chromosome 11p15. 4. Am J Hum Genet. 2003; 72 1551-1559.
97. Nesta F, Leyne M, Yosefy C, Simpson C, Dai D, Marshall JE, Hung J, Slaugenhaupt SA, Levine RA. New locus for autosomal dominant mitral valve prolapse on chromosome 13 clinical insights from genetic studies. Circulation. 2005; 112 2022-2030.
98. Kyndt F, Schott JJ, Trochu JN, Baranger F, Herbert O, Scott V, Fressinaud E, David A, Moisan JP, Bouhour JB, Le Marec H, Bénichou B. Mapping of X-linked myxomatous valvular dystrophy to chromosome Xq28. Am J Hum Genet. 1998; 62 627-632.
99. Nakamura F, Stossel TP, Hartwig JH. The filamins organizers of cell structure and function. Cell Adh Migr. 2011; 5 160-169.
100. Norris RA, Moreno-Rodriguez R, Wessels A, Merot J, Bruneval P, Chester AH, Yacoub MH, Hagège A, Slaugenhaupt SA, Aikawa E, Schott JJ, Lardeux A, Harris BS, Williams LK, Richards A, Levine RA, Markwald RR. Expression of the familial cardiac valvular dystrophy gene, filamin-A, during heart morphogenesis. Dev Dyn. 2010; 239 2118-2127.
101. Dalkilic I, Schienda J, Thompson TG, Kunkel LM. Loss of FilaminC (FLNc) results in severe defects in myogenesis and myotube structure. Mol Cell Biol. 2006; 26 6522-6534.
102. Zhou X, Tian F, Sandzén J, Cao R, Flaberg E, Szekely L, Cao Y, Ohlsson C, Bergo MO, Borén J, Akyürek LM. Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc Natl Acad Sci U S A. 2007; 104 3919-3924.
103. Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K. Filamin associates with Smads and regulates transforming growth factor-beta signaling. J Biol Chem. 2001; 276 17871-17877.
104. Cushing MC, Liao JT, Anseth KS. Activation of valvular interstitial cells is mediated by transforming growth factor-beta1 interactions with matrix molecules. Matrix Biol. 2005; 24 428-437.
105. Charitakis K, Basson CT. Degenerating heart valves fill them up with filamin? Circulation. 2007; 115 2-4.
106. Oyama MA, Chittur SV. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. Am J Vet Res. 2006; 67 1307-1318.
107. Peal DS, Lynch SN, Milan DJ. Patterning and development of the atrioventricular canal in zebrafish. J Cardiovasc Transl Res. 2011; 4 720-726.